Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

281.19 USD -4.07 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 Next >
Healthy Climate, Healthy Lives: Advancing Strategic Collaborations
Tags MIT Health & Healthcare Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
Tags Responsible Business & Employee Engagement NASDAQ:BIIB Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychop
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone... 
From Business Wire News Releases
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
Tags fossil fuel free climate action Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
Tags Health & Healthcare Environment Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy 
From GlobeNewswire News Releases
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
From GlobeNewswire News Releases
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
From ACN Newswire
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
From GlobeNewswire News Releases
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
From ACN Newswire
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
From GlobeNewswire News Releases
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
From GlobeNewswire News Releases
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
From GlobeNewswire News Releases
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
From ACN Newswire
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
From GlobeNewswire News Releases
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
From GlobeNewswire News Releases
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia 
From GlobeNewswire News Releases
Enel X Collaborates With Biogen to Electrify Take-Home Vehicle Fleet in North America
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
From GlobeNewswire News Releases
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Kenan Fellows Program and Biogen Foundation Collaborate to Advance Workforce Education
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
From GlobeNewswire News Releases
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
From GlobeNewswire News Releases
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg... 
From Business Wire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.